Therapy Areas: Oncology
Anocca announces USD47m from Series B Financing
22 July 2021 -

T-cell immunotherapy company Anocca AB reported on Wednesday the receipt of USD47m from its Series B financing led by Danske Bank, Swedbank Robur Ny Teknik, Ramsbury Invest.

This Series B financing was also led by significant family offices including Harald Mix, Robert Andreen, Mellby Gård, Nidoco and co-founder Mikael Blomqvist via Michano.

The funds will be used to further advance Anocca AB's industrialised cellular biology platform and progress its pipeline of TCR-T cellular therapies into Phase I/IIa clinical trials. Its highly industrialised cellular biology platform replicates human T-cell biology in the laboratory, to generate targeted T-cell therapies with broad applicability in oncology, infectious diseases and autoimmune disorders.

According to the company, its platform has delivered a broad pipeline of T-cell receptor (TCR) assets to generate novel TCR-modified T-cell therapies (TCR-T) against multiple antigen classes. TCR-T cellular therapies can unlock an immense target space inaccessible to biologics and CAR-T therapies and is emerging as an important treatment modality for many forms of cancer.



Related Headlines